Adragos Pharma, a globally operating CDMO, is on a mission to become the "Most Trusted CDMO," with a strong focus on expanding its production capacity in Japan. With a state-of-the-art manufacturing site in Kawagoe, they aim to meet the increasing demand for solid dosage forms, targeting a production capacity of 2 billion tablets in the near future. Specializing in small molecule solid preparations and various dosage forms, Adragos Pharma is well-equipped to support the bio-pharmaceutical sector and provide high-quality manufacturing standards.

President Yanagisawa's vision is to establish a robust site that can cater to the needs of their customers, ensuring consistent supply of high-quality products. With a dedicated team and a culture of excellence in quality and safety standards, Adragos Pharma is poised to be a key player in meeting the demands of the pharmaceutical market in Japan. Read more about their strategic expansion in Japan on their website.